Cargando…

Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

Novel characterization of patterns of adverse events (AEs) of kinase inhibitors (KIs) could reveal new insights on human molecular physiology and methods to improve the therapeutic index of KIs. Incidence and severity of AEs for each of 157 patients enrolled in sorafenib clinical trials were determi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karovic, S, Shiuan, EF, Zhang, SQ, Cao, H, Maitland, ML
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350995/ https://www.ncbi.nlm.nih.gov/pubmed/27443985 http://dx.doi.org/10.1111/cts.12408

Ejemplares similares

Decoding kinase-adverse event associations for small molecule kinase inhibitors
por: Gong, Xiajing, et al.
Publicado: (2022)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
por: Ostwal, Vikas, et al.
Publicado: (2017)

Sorafenib-Related Adverse Events in Predicting the Early Radiologic Responses of Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
por: Cerquetti, Lidia, et al.
Publicado: (2021)

Metabolic adverse events of multitarget kinase inhibitors: a systematic review
por: Acitelli, Elisa, et al.
Publicado: (2023)

Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib
por: Ross, Fiona A., et al.
Publicado: (2017)

A rare adverse reaction of sorafenib
por: Wang, Wenwu
Publicado: (2012)

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies
por: Karovic, Sanja, et al.
Publicado: (2014)

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges
por: Schneider, Tatiana C., et al.
Publicado: (2016)

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017)

Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome
por: Volpi, Stefano, et al.
Publicado: (2019)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Kinase Inhibitor Sorafenib Modulates Immunosuppressive Cell Populations in a Murine Liver Cancer Model
por: Cao, Mengde, et al.
Publicado: (2011)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
por: Corominas, Josep, et al.
Publicado: (2021)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature
por: Dammrich, Daniel J, et al.
Publicado: (2011)

Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study
por: Kaplan, David E., et al.
Publicado: (2018)

Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report
por: Gahr, Susanne, et al.
Publicado: (2012)

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
por: Califano, R., et al.
Publicado: (2015)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Sorafenib as an Inhibitor of RUVBL2
por: Nano, Nardin, et al.
Publicado: (2020)

Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution
por: España, Sofia, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib
por: Lee, Shou‐Wu, et al.
Publicado: (2018)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Endoscopic Versus Open Laminectomy for Lumbar Spinal Stenosis: An International, Multi-Institutional Analysis of Outcomes and Adverse Events
por: Chiu, Ryan G., et al.
Publicado: (2019)

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
por: Asano, Hiroki, et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib
por: Weng, Xie, et al.
Publicado: (2019)

Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database
por: Mizuno, Takahito, et al.
Publicado: (2021)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023)

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2022)

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer
por: Grevel, Joachim, et al.
Publicado: (2019)

Model‐based approach to identify predictors of paclitaxel‐induced myelosuppression in “real‐world” administration
por: Salem, Ahmed M., et al.
Publicado: (2023)

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer
por: Chrisoulidou, Alexandra, et al.
Publicado: (2015)

Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review
por: De Leo, Aurora, et al.
Publicado: (2021)

Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
por: Kawada, Kei, et al.
Publicado: (2022)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pm2uk8h6lcj611c8nuefog5poo